《大行》美银升再鼎医药(09688.HK)目标价至29.61元 重申中性评级

阿斯达克财经
Jun 06, 2025

美银研究报告指,再鼎医药(09688.HK) (ZLAB.US)  日前公布有关ZL-1310的正面数据,加上美国FDA已授出“快速通道认证”(Fast Track Designation),集团计划今年下半年开展第二类小细胞肺癌(2L SCLC)的第三阶段关键研究。基于以上临床进展,该行将集团2027年收入及净利润预测分别上调2.5%及14%,港股目标价由25.27港元升至29.61港元,美股...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10